Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 501–600 of 1,013
Xiao, W., Song, M., Li, W., Huang, J., Yang, G. Y., & Wang, Y. (2021) · Theranostics · doi:10.7150/thno.59342 · Cited by 111
“However, most chemotherapeutic drugs are identified as the substrates of the MDR, thereby limiting their clinical use [116].”
BackgroundNew Insights into the Mechanisms of Gastric Cancer Multidrug Resistance and Future Perspectives
Zhang, D., & Fan, D. (2010) · Future Oncology · doi:10.2217/fon.10.21 · Cited by 108
Sphingolipids and expression regulation of genes in cancer
Patwardhan, G. A., & Liu, Y. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.10.003 · Cited by 113
“Drug resistance of cancer cells is the outcome of multiple-gene interactions in cancer cells under the action of antineoplastic agents or irradiation [100-101].”
BackgroundComparison of mechanistic transport cycle models of ABC exporters
Szöllősi, D., Rose-Sperling, D., Hellmich, U. A., & Stockner, T. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.10.028 · Cited by 107
“While normally showing a protective function, ABCB1 frequently interferes with chemotherapy treatment by actively removing the medication, when cancer cells express the transporter [49,50].”
BackgroundAli, M. R. K., Panikkanvalappil, S. R., & El‐Sayed, M. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4124412 · Cited by 112
Improving Viral Protease Inhibitors to Counter Drug Resistance
Yılmaz, N. K., Swanstrom, R. I., & Schiffer, C. A. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.03.010 · Cited by 107
“Drug resistance can be conferred via various mechanisms, including decreased intracellular levels of drug (due to efflux pumps), altered gene expression, and changes in drug target [1–4].”
Yao, X., Chen, D., Zhao, B., Yang, B., Jin, Z., Fan, M., Tao, G., Qin, S., Yang, W., & He, Q. (2022) · Advanced Science · doi:10.1002/advs.202101965 · Cited by 107
de Jonge, H. J. M., Valk, P. J. M., Veeger, N. J. G. M., ter Elst, A., den Boer, M. L., Cloos, J. J., de Haas, V., van den Heuvel‐Eibrink, M. M., Kaspers, G. J. L., Zwaan, C. M., et al. (2010) · Blood · doi:10.1182/blood-2010-03-270991 · Cited by 108
Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges
Zhang, D., & Fan, D. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1369 · Cited by 110
O'Brien, C. L., Cavet, G., Pandita, A., Hu, X., Haydu, L. E., Mohan, S., Toy, K. J., Rivers, C. S., Modrusan, Z. D., Amler, L. C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0234 · Cited by 112
“MDR refers to the resistance of cancer cells to multiple classes of chemotherapeutic drugs that can be structurally and mechanistically unrelated and is related to the overexpression of a variety of proteins that act as ATP-dependent efflux pumps (5).”
BackgroundGlycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells
Nakano, A., Tsuji, D., Miki, H., Cui, Q., Sayed, S. M. E., Ikegame, A., Oda, A., Amou, H., Nakamura, S., Harada, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027222 · Cited by 130
“Various selective inhibitors of ABC transporters have been developed, and some are under clinical testing [24,25,26].”
BackgroundA thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance
Bidwell, G. L. I., Davis, A., Fokt, I., Priebe, W., & Raucher, D. (2007) · Investigational new drugs · doi:10.1007/s10637-007-9053-8 · Cited by 108
“Chemotherapeutics of the anthracycline, taxane, vinca alkaloid, epipodophyllotoxin, and antimetabolite families are especially susceptible to the development of multidrug resistance [8, 15, 16].”
BackgroundRole of protein kinase CK2 in antitumor drug resistance
Borgo, C., & Ruzzene, M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1292-y · Cited by 113
“In humans, three of them are known to mediate MDR: the P-glycoprotein (P-gp, also known as MDR1/ABCB1), the MDR-associated protein (MRP1, ABCC1), and the breast cancer resistance protein (BCRP, ABCG2) [12].”
BackgroundInfluentialXu, K., Liang, X., Cui, D., Wu, Y., Shi, W., & Liu, J. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21832 · Cited by 111
“develop multidrug resistance (MDR) to chemotherapy agents [2].”
BackgroundWang, H., Zhao, Y., Wang, H., Gong, J., He, H., Shin, M. C., Yang, V. C.-M., & Huang, Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.051 · Cited by 105
TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells
Flamant, L., Roegiers, E., Pierre, M., Hayez, A., Sterpin, C., De Backer, O., Arnould, T., Poumay, Y., & Michiels, C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-391 · Cited by 103
Das, C. K., Linder, B., Bonn, F., Rothweiler, F., Đikić, I., Michaelis, M., Cinatl, J. J., Mandal, M., & Kögel, D. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.001 · Cited by 112
Ji, N., Yang, Y., Cai, C., Lei, Z., Wang, J., Gupta, P., Shukla, S., Ambudkar, S. V., Kong, D., & Chen, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.007 · Cited by 111
“However, multidrug resistance (MDR) in cancer cells remains a major challenge that contributes to the failure of cancer chemotherapy [1,2].”
BackgroundBai, Z., Yao, C., Zhu, J., Xie, Y., Ye, X., Bai, R., & Xie, T. (2021) · Molecules · doi:10.3390/molecules26061499 · Cited by 115
“The increased efflux of various hydrophobic cytotoxic drugs mediated by the ATP-binding cassette (ABC) transporters, including P-glycoprotein (P-gp, also known as MDR1 or ABCB1) and breast cancer resistance protein (BCRP), is a common drug resistance mechanism [52].”
BackgroundTissue transglutaminase-mediated chemoresistance in cancer cells
Verma, A., & Mehta, K. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.06.002 · Cited by 113
Bankstahl, J. P., Kuntner, C., Abrahim, A., Karch, R., Stanek, J., Wanek, T., Wadsak, W., Kletter, K., Müller, M., Löscher, W., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.051235 · Cited by 105
“To overcome P-gp–mediated drug resistance, several newgeneration P-gp modulators have been developed, and they have been shown to inhibit P-gp with good selectivity and high potency without causing significant side effects (11).”
BackgroundSosnik, A. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.002 · Cited by 111
Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals
Seo, J.-W., Fu, K. X., Correa, S., Eisenstein, M. S., Appel, E. A., & Soh, H. T. (2022) · Science Advances · doi:10.1126/sciadv.abk2901 · Cited by 110
Bai, J., Swartz, D. J., Protasevich, I. I., Brouillette, C. G., Harrell, P. M., Hildebrandt, E. F., Gasser, B., Mattanovich, D., Ward, A. B., Chang, G. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022577 · Cited by 114
“has been a target for improving cancer treatment since its discovery more than three decades ago [2,3,4].”
BackgroundMasui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 128
Tumor microenvironment and nanotherapeutics.
Upreti, M., Jyoti, A., & Sethi, P. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.08.11 · Cited by 133
Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance
Cho, Y., & Kim, Y. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00764 · Cited by 107
“Until ixabepilone was launched, efforts to develop drugs targeting ABC transporters had been a driving force in the development of first-, second-, and third-generation P-gp inhibitors (90, 91).”
BackgroundWang, J., Hu, L., Zhang, H., Fang, Y., Wang, T., & Wang, H. (2021) · Advanced Materials · doi:10.1002/adma.202104704 · Cited by 104
Durmuş, S., Sparidans, R. W., van Esch, A., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1442-z · Cited by 114
“To date, a number of ABC transporters, including ABCB1 and ABCG2, have been associated with resistance to chemotherapy in several types of cancers, including breast cancer, where they confer resistance to a wide range of drugs (32 – 35).”
Adar, Y., Stark, M., Bram, E. E., Nowak-Sliwinska, P. M., van den Bergh, H., Szewczyk, G. M., Sarna, T., Składanowski, A., Griffioen, A. W., & Assaraf, Y. G. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.30 · Cited by 105
Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Jin, Y.-H., Hu, H., Qiao, M., Zhu, J., Qi, J.-W., Hu, C.-J., Zhang, Q., & Chen, D. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.01.032 · Cited by 108
Smart Mesoporous Nanomaterials for Antitumor Therapy
Martínez-Carmona, M., Colilla, M., & Vallet-Regí, M. (2015) · Nanomaterials · doi:10.3390/nano5041906 · Cited by 102
“Multidrug resistance (MDR) is the most important impediment for successful chemotherapy even with targeted drugs or/and combination chemotherapy [200].”
BackgroundCombined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy
Schmitt, F., Govindaswamy, P., Zava, O., Süß‐Fink, G., Juillerat‐Jeanneret, L., & Therrien, B. (2008) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-008-0427-y · Cited by 102
Chemotherapy-Resistant Metastatic Breast Cancer
Marquette, C., & Nabell, L. M. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0184-6 · Cited by 112
Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells
Roy, M., & Mukherjee, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.3.1403 · Cited by 103
“Curcumin induced down regulation of MDR genes were earlier observed by Choi et al in mouse leukemia cell line (Choi et al., 2008).”
BackgroundInfluentialMichaelis, M., Rothweiler, F., Klassert, D., von Deimling, A., Weber, K., Fehse, B., Kammerer, B., Doerr, H. W., & Cinatl, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1856 · Cited by 100
“MRP-1 is another family member of the ABC transporters that was shown to be involved in cancer cell chemoresistance (17, 18).”
BackgroundThe role of glucuronidation in drug resistance
Mazerska, Z., Mróz, A., Pawłowska, M., & Augustin, E. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.009 · Cited by 107
Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer
Riquelme, I., Letelier, P. J., Riffo‐Campos, Á. L., Brebi, P., & Roa, J. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030424 · Cited by 107
“Previous studies have clarified several cytological mechanisms of drug resistance of cancer cells, such as increased efflux of hydrophobic drugs, decreased uptake of water-soluble drugs and other changes influencing the capacity of cytotoxic drugs to kill cells, including alterations in cell cycle and proliferation, e…”
BackgroundBio-Inspired Protein-Based Nanoformulations for Cancer Theranostics
Gou, Y., Miao, D., Zhou, M., Wang, L., Zhou, H., & Su, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00421 · Cited by 107
“…have been disappointing in efficacy due to multidrug resistance (MDR) and severe side effects (Gelperina et al., 2005; Pérez-Tomás, 2006; Szakács et al., 2006; Ge and Liu, 2013); (3) the cancer therapeutic biological agents (inclusive of antibodies, proteins and nucleic acids), the new…”
BackgroundPolymeric Nanoparticles for the Treatment of Malignant Gliomas
Mahmoud, B. S., Alamri, A. H., & McConville, C. (2020) · Cancers · doi:10.3390/cancers12010175 · Cited by 110
Mohanty, A. R., Pharaon, R. R., Nam, A., Salgia, S. K., Kulkarni, P., & Massarelli, E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1740680 · Cited by 104
“membranes play a critical role in multi-drug resistance in cancer cells by effluxing the drugs out of the cells [71,72].”
BackgroundWu, G., Otegui, M. S., & Spalding, E. P. (2010) · The Plant Cell · doi:10.1105/tpc.110.078360 · Cited by 103
“Because ABCB1, the most similar ABC transporter in humans, is responsible for drug resistance in tumors (Szakács et al., 2006), this study may have also a broader significance in cancer research.”
BackgroundInfluentialFüredi, A., Szebényi, K., Tóth, S., Cserepes, M., Hámori, L., Nagy, V., Karai, E., Vajdovich, P., Imre, T., Szabó, P., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.010 · Cited by 100
Self-citationFang, C., Kievit, F. M., Veiseh, O., Stephen, Z. R., Wang, T., Lee, D., Ellenbogen, R. G., & Zhang, M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.028 · Cited by 100
“MDR is characterized by the overexpression of ATP-binding cassette (ABC) transporters which increase the efflux of chemotherapeutic drugs out of cancer cells before the drug can reach its intracellular site of action [2].”
BackgroundChen, Q., Jiao, D., Wang, J., Hu, H., Tang, X., Chen, J., Mou, H., & Lu, W. (2016) · Oncotarget · doi:10.18632/oncotarget.8229 · Cited by 106
Xia, F., Hou, W., Zhang, C., Zhi, X., Cheng, J. Q., de la Fuente, J. M., Song, J., & Cui, D. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.12.034 · Cited by 101
Chen, S., Wu, J., Jiao, K., Wu, Q., Ma, J., Chen, D., Kang, J., Zhao, G., Shi, Y., Fan, D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0950-x · Cited by 101
Yu, D., Feng, J., You, H., Zhou, S., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Marine Drugs · doi:10.3390/md20010069 · Cited by 108
“One of the most common mechanisms of acquired drug resistance relies on drug efflux of cancer cells mediated by ATP binding box (ABC) transporters [85].”
BackgroundThe Role of MicroRNAs in Chemoresistance
Bahreini, F., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_336-1 · Cited by 100
Wu, C., Shukla, S., Calcagno, A. M., Hall, M. D., Gottesman, M. M., & Ambudkar, S. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2005 · Cited by 100
“Although a number of these agents have shown promise in vitro , they have not been successful in clinical trials, probably due to interference with the function of endogenous P-glycoprotein and suboptimal trial design (18).”
BackgroundSelf-citationInhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals
Nabekura, T., Yamaki, T., Hiroi, T., Ueno, K., & Kitagawa, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.11.010 · Cited by 101
“[5] Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM.”
Structure and Function of ABCG2-Rich Extracellular Vesicles Mediating Multidrug Resistance
Goler-Baron, V., & Assaraf, Y. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016007 · Cited by 104
“These ATP-driven MDR efflux transporters differ markedly in substrate specificity, tissue distribution and intracellular localization [1,4,5,6].”
BackgroundHuman ovarian cancer stem cells
Bapat, S. A. (2010) · Reproduction · doi:10.1530/rep-09-0389 · Cited by 111
Esser, A. T., Smith, K. C., Gowrishankar, T. R., & Weaver, J. C. (2007) · Technology in Cancer Research & Treatment · doi:10.1177/153303460700600402 · Cited by 107
Hu, T., To, K. K. W., Wang, L., Zhang, L., Lu, L., Shen, J., Chan, R. L. Y., Li, M., Yeung, J. H. K., & Cho, C. H. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.06.013 · Cited by 99
Diospyros, an under-utilized, multi-purpose plant genus: A review
Rauf, A., Uddin, G., Patel, S. V., Khan, A., Halim, S. A., Bawazeer, S. S., Ahmad, K., Muhammad, N., & Mubarak, M. S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.012 · Cited by 99
Zhou, M., Li, L., Li, L., Lin, X., Wang, F., Li, Q., & Huang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.005 · Cited by 99
Role of ATP-binding cassette transporters in cancer initiation and progression
Nobili, S., Lapucci, A., Landini, I., Coronnello, M., Roviello, G., & Mini, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.006 · Cited by 97
Recent advances in targeted nanomedicine as promising antitumor therapeutics
Hejmady, S., Pradhan, R., Alexander, A., Agrawal, M., Singhvi, G., Gorain, B., Tiwari, S., Kesharwani, P., & Dubey, S. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.031 · Cited by 99
Yu, Y., Wang, Z., Zhang, L., Yao, H.-J., Zhang, Y., Li, R., Ju, R.-J., Wang, X., Zhou, J., Li, N., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.085 · Cited by 102
Antibody-based targeting of the tumor vasculature
Schliemann, C., & Neri, D. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.08.002 · Cited by 105
Albert, B. J., McPherson, P. A., O'Brien, K., Czaicki, N. L., DeStefino, V. J., Osman, S., Li, M., Day, B. W., Grabowski, P. J., Moore, M. J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0051 · Cited by 99
“A common mechanism of MDR is the overexpression of P-glycoprotein (ABCB1), which often exports aromatic ring–containing small molecules (41).”
BackgroundInfluentialA Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Vasalou, C., Helmlinger, G., & Gomes, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118977 · Cited by 98
Kuete, V., Fankam, A. G., Wiench, B., & Efferth, T. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/285903 · Cited by 101
Liu, J., Ma, X., Jin, S., Xue, X., Zhang, C., Wei, T., Guo, W., & Liang, X. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00311 · Cited by 102
Suehiro, S., Ohnishi, T., Yamashita, D., Kohno, S., Inoue, A., Nishikawa, M., Ohue, S., Tanaka, J., & Kunieda, T. (2018) · Journal of neurosurgery · doi:10.3171/2017.6.jns162398 · Cited by 98
Guo, B., Wu, M., Shi, Q., Dai, T., Xu, S., Jiang, J., & Liu, B. (2020) · Chemistry of Materials · doi:10.1021/acs.chemmater.0c01187 · Cited by 97
Dawood, D. H., Nossier, E. S., Ali, M. M., & Mahmoud, A. E. E.-D. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103916 · Cited by 98
Liu, J., Zhu, C., Xu, L., Wang, D., Liu, W., Zhang, K., Zhang, Z., & Shi, J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c03042 · Cited by 99
Gao, M., Miao, L., Liu, M., Li, C., Yu, C., Yan, H., Yin, Y., Wang, Y., Qi, X., & Ren, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10845 · Cited by 96
“A broad range of anti-cancer drugs are extruded by MRP1 [10, 11].”
BackgroundNanomedicines for advanced cancer treatments: Transitioning towards responsive systems
van Elk, M., Murphy, B. P., Eufrásio-da-Silva, T., O’Reilly, D. P., Vermonden, T., Hennink, W. E., Duffy, G. P., & Ruiz‐Hernández, E. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.013 · Cited by 104
“Another major problem is that cancer cells can become resistant towards chemotherapeutic drugs (Baguley, 2010; Szakács et al., 2006).”
Tucker, D. W., Getchell, C. R., McCarthy, E. T., Öhman, A., Sasamoto, N., Xu, S., Ko, J. Y., Gupta, M., Shafrir, A. L., Medina, J. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1958 · Cited by 99
“Since the dynamic regulation of 5-hmC levels play key roles in the development and pluripotency of somatic stem cells (14–16), it is possible that global 5hmC patterns may also contribute to the maintenance and regulation of cancer stem cells (CSC), which have been implicated in chemoresistance and poor clinical outco…”
BackgroundChen, X., Wang, Z., Tong, F., Dong, X., Wu, G., & Zhang, R. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.047 · Cited by 97
RetractedDefect self-assembly of metal-organic framework triggers ferroptosis to overcome resistance
Peng, H., Zhang, X., Yang, P., Zhao, J., Zhang, W., Feng, N., Yang, W., & Tang, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.12.018 · Cited by 101
“For example, the development of pump inhibitors and cytotoxic agents against drug resistance, targeting the downregulation of MDR genes, evades or exploits efflux by ATP-binding cassette transporters [6].”
BackgroundABC transporters in breast cancer: their roles in multidrug resistance and beyond
Modi, A., Roy, D., Sharma, S., Vishnoi, J. R., Pareek, P., Elhence, P. A., Sharma, P., & Purohit, P. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2091578 · Cited by 104
Understanding resistance to combination chemotherapy
Pritchard, J. R., Lauffenburger, D. A., & Hemann, M. T. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.003 · Cited by 108
“This pump can mediate the efflux of numerous drugs used in combinatorial regimens, including anthracyclines, taxanes, and Vinca alkaloids (Szakacs et al., 2006).”
BackgroundHeffeter, P., Jakupec, M. A., Körner, W., Chiba, P., Pirker, C., Dornetshuber, R., Elbling, L., Sutterlüty, H., Micksche, M., Keppler, B. K., et al. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.002 · Cited by 97
“Thus our data on collateral sensitivity against KP772 also of ABCC1- and ABCG2expressing cells suggest for the first time that a general ABC transporter-mediated mechanism can underlie hypersensitivity of MDR cells against a cytotoxic drug.”
BackgroundInfluentialBlakeley, J. O. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0036-8 · Cited by 111
“Despite considerable efforts to advance this approach, results have been mixed in systemic cancers and limited by enhanced toxicities of the chemotherapies [ 9 ].”
BackgroundResultdos Santos, S. C., Teixeira, M. C., Dias, P. J., & Sá‐Correia, I. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00180 · Cited by 103
“…of infectious diseases, as well as food preservation and crop protection strategies, due to the emergence of resistant cancer cell lines, pathogenic strains, and resistant weed species (Prasad and Kapoor, 2005; De Waard et al., 2006; Szakács et al., 2006; Hall et al., 2009; Morschhauser, 2010).”
BackgroundPolymer assembly: Promising carriers as co-delivery systems for cancer therapy
Li, N., Zhao, L., Qi, L., Li, Z., & Luan, Y. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2015.10.009 · Cited by 97
Xia, C. Q., & Smith, P. G. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079129 · Cited by 103
“The genes responsible for encoding these proteins, as well as other genes that encode ABC transporters known to be involved in anticancer drug resistance, are shown in Table 1, along with the known drug substrates for each MDR protein (Szakács et al., 2006; Moitra et al., 2011).”
BackgroundInfluentialCapsaicin and Piperine Can Overcome Multidrug Resistance in Cancer Cells to Doxorubicin
Li, H., Krstin, S., Wang, S., & Wink, M. (2018) · Molecules · doi:10.3390/molecules23030557 · Cited by 106
“This resistance, intrinsic or acquired, can be attributed to drug efflux and drug metabolism [4].”
BackgroundGreenhalgh, K., Ramiro‐Garcia, J., Heinken, A., Ullmann, P., Bintener, T., Pacheco, M. P., Bagińska, J., Shah, P., Frachet, A., Halder, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.001 · Cited by 101
“In fact, overexpression of these transporters is the most commonly observed mechanism through which cancer cells become drug resistant (Davis and Tew, 2017; Szakács et al., 2006).”
Lin, G., Revia, R. A., & Zhang, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202007096 · Cited by 103
Resistance to Intervention: Paclitaxel in Breast Cancer
Dan, V. M., Raveendran, R. S., & Baby, S. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520999201214234421 · Cited by 105
Hubensack, M., Müller, C., Höcherl, P., Fellner, S., Spruß, T., Bernhardt, G., & Buschauer, A. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0323-9 · Cited by 114
“Valspodar inhibits the CYP 3A4 (Fischer et al. 1998), which is responsible for paclitaxel metabolism, whereas such drug–drug interactions are not known for the new modulators, elacridar and tariquidar (Szakacs et al. 2006; Ward and Azzarano 2004; Labrie et al. 2007).”
Non-viral nanocarriers for siRNA delivery in breast cancer
Zhang, J., Li, X., & Huang, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.037 · Cited by 106
“ATP-binding cassette (ABC) transporters are the key component of the energy-dependent efflux system involved in the multidrug-resistant cancer phenotype [79].”
BackgroundLessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
“Often, tumors display multiple drug resistance (MDR), which is one of the major reasons for the ineffectiveness and toxicity of chemotherapeutic agents [122].”
BackgroundKuete, V., Mbaveng, A. T., Sandjo, L. P., Zeino, M., & Efferth, T. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.07.010 · Cited by 97
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Qin, Y., Han, S., Yu, Y., Ding, Q., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.15953 · Cited by 111
“63 Surviving cancer cells become resistant to therapeutic drugs, and reduced sensitivity leads to tumour recurrence and metastasis, so MDR is considered the main cause of treatment failure in more than 90% of patients.”
miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression
Mu, W., Hu, C., Zhang, H., Qu, Z., Cen, J., Qiu, Z., Li, C., Ren, H., Li, Y., He, X., et al. (2015) · Cell Research · doi:10.1038/cr.2015.23 · Cited by 99
Near-infrared light-triggered nano-prodrug for cancer gas therapy
Liu, R., Peng, Y., Lu, L., Peng, S., Chen, T., & Zhan, M. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01078-x · Cited by 97
“Photothermal therapy‐triggered SO2 prodrug MDR of cancer cells is one of the main obstacles hindering the effect of cancer chemotherapy [227].”
BackgroundDrug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer
Lee, S., Kim, H. J., Kim, S. Y., Kwon, M. K., Kim, S., Cho, A. E.-H., Yun, M., Shin, J., & Yoo, K. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.068 · Cited by 97
“To overcome MDR, many MDR transporter inhibitors have been developed; some are in clinical trials, but none are currently in clinical use [8].”
BackgroundSonowal, H., Pal, P. B., Wen, J.-J., Awasthi, S., Ramana, K. V., & Sk, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-03284-w · Cited by 101
Huang, S., Chen, M., Shen, Y., Shen, W., Guo, H., Gao, Q., & Zou, X. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.10.011 · Cited by 94
miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2
Xu, K., Liang, X., Shen, K., Cui, D., Zheng, Y., Xu, J., Fan, Z., Qiu, Y., Li, Q., Ni, L., et al. (2012) · Biochemical Journal · doi:10.1042/bj20120386 · Cited by 93
MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp
Lu, C., Shan, Z., Li, C., & Yang, L. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.139 · Cited by 94
Wang, H., Liang, Y., Yin, Y., Zhang, J., Su, W., White, A. M., Jiang, B., Xu, J., Zhang, Y., Stewart, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20588-0 · Cited by 95
RetractedJain, R., Hussein, M. A., Pierce, S., Martens, C., Shahagadkar, P., & Munirathinam, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106138 · Cited by 106
“Cancer resistance is a significant problem that demands the usage of multiple targeted treatments [25].”
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.